MedTrace Logo

Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients

NCT02311647 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2014-12-23

No results posted yet for this study

Summary

The aim of this multi-center study is to assess the effects of Tamoxifen on the uterine cavity and endometrial abnormalities in young premenopausal women diagnosed with breast cancer.

The research contains two parts: a clinical study and a laboratory study.

* Clinical part: to evaluate the association between tamoxifen treatment and uterine abnormalities.
* Laboratory part: to investigate the effect of Tamoxifen treatment on endometrial tissue, by exploring the molecular aspect of endometrial receptivity.

Conditions

  • Endometrial Receptivity Post Tamoxifen Exposure

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Dror Meirov, MD · Sheba Medical Center

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-01-31
Completion
2017-02-28

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02311647 on ClinicalTrials.gov